Taylor, "Role of two forms of hepatitis delta virus
antigen: Evidence for a mechanism of self-limiting genome replication," Journal of Virology, vol.
Hepatitis delta virus
: from biological and medical aspects to current and investigational therapeutic options.
Prevalence of hepatitis delta virus
(HDV) infection in chronic hepatitis B patients with unusual clinical pictures.
Critique: Deftly organized and presented in six major sections (Introduction to Hepatitis B Virus; Virology; Pathogenesis and Natural History; Animal Models; Prevention, Treatment, Control, and Eradication; and Hepatitis Delta Virus
), "The Hepatitis B and Delta Viruses" will prove to be a critically essential reference for virologists, clinical and laboratory investigators, and physicians interested in reducing the burden of liver disease caused by HBV and HDV.
Hepatitis Delta virus
genotype 8 infection in Northeast Brazil: Inheritance from African slaves.
(44.) Hartwig D, Schutte C, Warnecke J, Dorn I, Hennig H, Kirchner H, et al., The large form of ADAR 1 is responsible for enhanced hepatitis delta virus
RNA editing in interferonalpha-stimulated host cells.
(Nasdaq: EIGR), focused on the development and commercialization of targeted therapies for rare and ultra-rare diseases, today announced that the Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for peginterferon lambda (Lambda) for the treatment of hepatitis delta virus
David Cory, chief executive officer at Eiger, said, 'I want to thank David for his service to Eiger, particularly in leading the Company's hepatitis delta virus
German biotechnology company MYR Pharma disclosed on Tuesday the receipt of the Promising Innovative Medicine (PIM) designation for its lead compound Bulevirtide (Myrcludex) for the indication of chronic hepatitis delta virus
(HDV) infection, from the British Medicines and Healthcare products Regulatory Agency (MHRA).
Tenthoff remains focused on Eiger's hepatitis delta virus
franchise with full 48-week Phase II interferon lambda data at the annual American Association for the study of Liver Diseases meeting in November and the Phase III D-LIVR trial start of lonafarnib in Q4.
According to the companies, the proposed merger will create a clinical-stage company with a diversified development portfolio of product candidates addressing novel targets for four distinct orphan diseases: Hepatitis Delta Virus
, bariatric surgery-induced hyperinsulinemic hypoglycemia, pulmonary arterial hypertension, and lymphedema.
To the Editor: Hepatitis delta virus
(HDV) is a small RNA virus that infects and persists only in persons whose samples test positive for hepatitis B surface antigen (HB-sAg) (1).